TABLE 1.
Demographics and clinical description of 25 COVID-19 cases
| Demographic | No. (%) of patientsa |
P value | ||
|---|---|---|---|---|
| Pneumonia | No pneumonia | Total | ||
| All patients | 5 (20) | 20 (80) | 25 (100) | |
| Mean (± SD) age | 47.4 (10.5) | 36.5 (13.4) | 38.68 (13.4) | 0.105 |
| Male | 3 (60) | 9 (45) | 12 (48) | 0.459 |
| Female | 2 (40) | 11 (55) | 13 (52) | |
| Imported cases | 4 (80) | 17 (75) | 21 (84) | 0.720 |
| Europe | 0 | 6 (30) | 6 (24) | |
| America | 1 (20) | 3 (15) | 4 (16) | |
| Africa | 1 (20) | 2 (10) | 3 (12) | |
| Asia-pacific | 2 (40) | 6 (30) | 8 (32) | |
| Indigenous cases | 1 (20) | 3 (15) | 4 (16) | |
| Occupation | 0.720 | |||
| Student | 0 | 5 (25) | 5 (20) | |
| Military | 1 (20) | 2 (10) | 3 (12) | |
| Business | 1 (20) | 5 (25) | 6 (24) | |
| Professional | 2 (40) | 6 (30) | 8 (32) | |
| Other | 1 (20) | 2 (10) | 3 (12) | |
| Subject symptoms | ||||
| Fever | 3 (60) | 9 (45) | 12 (48) | 0.459 |
| Cough | 3 (60) | 9 (45) | 12 (48) | 0.459 |
| Diarrhea | 1 (20) | 6 (30) | 7 (28) | 0.564 |
| Rhinorrhea | 0 | 7 (35) | 7 (28) | 0.161 |
| Sore throat | 0 | 6 (30) | 6 (24) | 0.219 |
| General soreness | 2 (40) | 4 (20) | 6 (24) | 0.343 |
| Abnormal smell | 0 | 6 (30) | 6 (24) | 0.219 |
| Abnormal taste | 0 | 5 (25) | 5 (20) | 0.292 |
| Avg no. (SD) of symptoms | 2.4 (0.54) | 3.1 (2.28) | 2.9 (2.06) | 0.539 |
| Laboratory data | ||||
| WBC 109/L mean (SD) | 6,252 (2,653) | 5,834 (1,880) | 5,963 (1,962) | 0.865 |
| Lymphocytes 109/L mean (SD) | 1,211 (616) | 1,511 (628) | 1,481 (630) | 0.347 |
| CRP mg/dL mean (SD) | 1.16 (0.91) | 0.57 (0.72) | 0.67 (0.78) | 0.143 |
| Creatinine mg/dL mean (SD) | 0.96 (0.29) | 0.76 (0.13) | 0.80 (0.18) | 0.194 |
| ALT U/L mean (SD) | 46.8 (22.8) | 26.6 (13.9) | 30.6 (17.5) | 0.018 |
| LDH U/L mean (SD) | 258.8 (60.3) | 214.2 (42.4) | 224.4 (49.3) | 0.074 |
| Antiviral agentb | 4 (80) | 7 (35) | 11 (44) | 0.096 |
| Immune modulatorc | 4 (80) | 13 (65) | 17 (68) | 0.475 |
| Steroid | 2 (40) | 1 (5) | 3 (12) | 0.091 |
a
Data are presented as number of patients (%) unless otherwise indicated.
b
Among pneumonia cases, 2 had lopinavir, 1 had both lopinavir and remdesivir, and 1 had oseltamivir. Among nonpneumonia cases, 6 had oseltamivir, and 1 had lopinavir.
c
Hydroxychloroquine had been used in 4 pneumonia cases and 12 nonpneumonia cases. Colchicine had been used in 1 pneumonia case and 1 nonpneumonia case.